AstraZeneca beats Q3 estimates and outlines 'Reshaping for Sustainable Growth'
with up to $2B in one-off restructuring charges for $1.5B savings
- Q3 EPS $2.79, up 17% YoY, on revenue $16.2B, up 7% YoY, beating analyst estimates.
- Q3 net profit rose 23%, with AstraZeneca reaffirming its full-year guidance.
- "Reshaping for Sustainable Growth" will run largely through 2029, targeting $1.5B in annual cost savings reinvested in the drug pipeline.
- CEO Pascal Soriot projects over $20 billion in peak sales potential from 2027 drug trial readouts.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.